The presence of tumour cells in the circulation may predict disease recurrence and metastasis. To improve on existing methods of cytological or immunocytological detection, we have developed a sensitive and quantitative technique for the detection of carcinoma cells in blood, using the reverse transcriptase polymerase chain reaction (RT-PCR) identifying transcripts of the pancarcinoma-associated tumour marker EGP-2 (KSA or 17-1A antigen). The amount of EGP2 mRNA was quantified using an internal recombinant competitor RNA standard with known concentration and which is both reversely transcribed and co-amplified in the same reaction, allowing for a reliable assessment of the initial amount of EGP2 mRNA in the sample. Calibration studies, seeding blood with MCF-7 breast carcinoma cells, showed that the assay can detect ten tumour cells among 1.0 x 106 leucocytes. The PCR assay revealed that normal bone marrow expresses low levels of EGP2 mRNA, although immunocytochemistry with the anti-EGP2 MAb MOC31 could not identify any positively stained cell. Analyses using this RT-PCR assay may prove to have applications to the assessment of circulating tumour cells in clinical samples.
CITATION STYLE
Helfrich, W., Ten Poele, R., Meersma, G. J., Mulder, N. H., De Vries, E. G. E., De Leij, L., & Smit, E. F. (1997). A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood. British Journal of Cancer, 76(1), 29–35. https://doi.org/10.1038/bjc.1997.331
Mendeley helps you to discover research relevant for your work.